The double homeodomain protein DUX4c is associated with regenerating muscle fibers and RNA-binding proteins.


Journal

Skeletal muscle
ISSN: 2044-5040
Titre abrégé: Skelet Muscle
Pays: England
ID NLM: 101561193

Informations de publication

Date de publication:
07 03 2023
Historique:
received: 20 07 2021
accepted: 30 11 2022
entrez: 7 3 2023
pubmed: 8 3 2023
medline: 10 3 2023
Statut: epublish

Résumé

We have previously demonstrated that double homeobox 4 centromeric (DUX4C) encoded for a functional DUX4c protein upregulated in dystrophic skeletal muscles. Based on gain- and loss-of-function studies we have proposed DUX4c involvement in muscle regeneration. Here, we provide further evidence for such a role in skeletal muscles from patients affected with facioscapulohumeral muscular dystrophy (FSHD). DUX4c was studied at RNA and protein levels in FSHD muscle cell cultures and biopsies. Its protein partners were co-purified and identified by mass spectrometry. Endogenous DUX4c was detected in FSHD muscle sections with either its partners or regeneration markers using co-immunofluorescence or in situ proximity ligation assay. We identified new alternatively spliced DUX4C transcripts and confirmed DUX4c immunodetection in rare FSHD muscle cells in primary culture. DUX4c was detected in nuclei, cytoplasm or at cell-cell contacts between myocytes and interacted sporadically with specific RNA-binding proteins involved, a.o., in muscle differentiation, repair, and mass maintenance. In FSHD muscle sections, DUX4c was found in fibers with unusual shape or central/delocalized nuclei (a regeneration feature) staining for developmental myosin heavy chain, MYOD or presenting intense desmin labeling. Some couples of myocytes/fibers locally exhibited peripheral DUX4c-positive areas that were very close to each other, but in distinct cells. MYOD or intense desmin staining at these locations suggested an imminent muscle cell fusion. We further demonstrated DUX4c interaction with its major protein partner, C1qBP, inside myocytes/myofibers that presented features of regeneration. On adjacent muscle sections, we could unexpectedly detect DUX4 (the FSHD causal protein) and its interaction with C1qBP in fusing myocytes/fibers. DUX4c upregulation in FSHD muscles suggests it contributes not only to the pathology but also, based on its protein partners and specific markers, to attempts at muscle regeneration. The presence of both DUX4 and DUX4c in regenerating FSHD muscle cells suggests DUX4 could compete with normal DUX4c functions, thus explaining why skeletal muscle is particularly sensitive to DUX4 toxicity. Caution should be exerted with therapeutic agents aiming for DUX4 suppression because they might also repress the highly similar DUX4c and interfere with its physiological role.

Sections du résumé

BACKGROUND
We have previously demonstrated that double homeobox 4 centromeric (DUX4C) encoded for a functional DUX4c protein upregulated in dystrophic skeletal muscles. Based on gain- and loss-of-function studies we have proposed DUX4c involvement in muscle regeneration. Here, we provide further evidence for such a role in skeletal muscles from patients affected with facioscapulohumeral muscular dystrophy (FSHD).
METHODS
DUX4c was studied at RNA and protein levels in FSHD muscle cell cultures and biopsies. Its protein partners were co-purified and identified by mass spectrometry. Endogenous DUX4c was detected in FSHD muscle sections with either its partners or regeneration markers using co-immunofluorescence or in situ proximity ligation assay.
RESULTS
We identified new alternatively spliced DUX4C transcripts and confirmed DUX4c immunodetection in rare FSHD muscle cells in primary culture. DUX4c was detected in nuclei, cytoplasm or at cell-cell contacts between myocytes and interacted sporadically with specific RNA-binding proteins involved, a.o., in muscle differentiation, repair, and mass maintenance. In FSHD muscle sections, DUX4c was found in fibers with unusual shape or central/delocalized nuclei (a regeneration feature) staining for developmental myosin heavy chain, MYOD or presenting intense desmin labeling. Some couples of myocytes/fibers locally exhibited peripheral DUX4c-positive areas that were very close to each other, but in distinct cells. MYOD or intense desmin staining at these locations suggested an imminent muscle cell fusion. We further demonstrated DUX4c interaction with its major protein partner, C1qBP, inside myocytes/myofibers that presented features of regeneration. On adjacent muscle sections, we could unexpectedly detect DUX4 (the FSHD causal protein) and its interaction with C1qBP in fusing myocytes/fibers.
CONCLUSIONS
DUX4c upregulation in FSHD muscles suggests it contributes not only to the pathology but also, based on its protein partners and specific markers, to attempts at muscle regeneration. The presence of both DUX4 and DUX4c in regenerating FSHD muscle cells suggests DUX4 could compete with normal DUX4c functions, thus explaining why skeletal muscle is particularly sensitive to DUX4 toxicity. Caution should be exerted with therapeutic agents aiming for DUX4 suppression because they might also repress the highly similar DUX4c and interfere with its physiological role.

Identifiants

pubmed: 36882853
doi: 10.1186/s13395-022-00310-y
pii: 10.1186/s13395-022-00310-y
pmc: PMC9990282
doi:

Substances chimiques

C1QBP protein, human 0
Carrier Proteins 0
Desmin 0
Homeodomain Proteins 0
Mitochondrial Proteins 0
DUX4L9 protein, human 0
Transcription Factors 0
RNA-Binding Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5

Informations de copyright

© 2023. The Author(s).

Références

J Cell Mol Med. 2013 Jan;17(1):76-89
pubmed: 23206257
EMBO Rep. 2012 Aug;13(8):741-9
pubmed: 22732842
Hybridoma (Larchmt). 2011 Apr;30(2):125-30
pubmed: 21529284
Hum Mol Genet. 2015 Oct 15;24(20):5901-14
pubmed: 26246499
FASEB J. 2008 Jun;22(6):1694-701
pubmed: 18198216
Muscle Nerve. 2015 Oct;52(4):521-6
pubmed: 25704033
Mol Cancer. 2006 Jun 08;5:23
pubmed: 16762066
Nature. 2005 Nov 24;438(7067):512-5
pubmed: 16306994
Nat Rev Genet. 2020 Mar;21(3):191-201
pubmed: 31848477
FASEB J. 2004 Nov;18(14):1761-3
pubmed: 15364895
PLoS One. 2008;3(10):e3389
pubmed: 18852887
J Microsc. 2001 Dec;204(Pt 3):196-202
pubmed: 11903796
Cell Cycle. 2009 Jul 1;8(13):2125
pubmed: 19440039
Neurology. 2003 Jul 22;61(2):178-83
pubmed: 12874395
iScience. 2019 Mar 29;13:229-242
pubmed: 30870781
J Cell Mol Med. 2010 Jan;14(1-2):275-89
pubmed: 18505476
Scand J Clin Lab Invest Suppl. 2001;234:93-9
pubmed: 11713986
J Neuromuscul Dis. 2018;5(3):315-319
pubmed: 30103349
Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18157-62
pubmed: 17984056
PLoS Genet. 2017 Mar 8;13(3):e1006658
pubmed: 28273136
Semin Immunol. 2019 Oct;45:101338
pubmed: 31744753
Dev Cell. 2015 Jul 27;34(2):181-91
pubmed: 26143994
RNA Biol. 2014;11(8):1019-30
pubmed: 25531407
Hum Mol Genet. 2019 Jul 1;28(13):2224-2236
pubmed: 31067297
J Cell Sci. 2018 Apr 13;131(8):
pubmed: 29654160
Hum Mol Genet. 2019 Apr 1;28(7):1064-1075
pubmed: 30445587
Mol Cell Biol. 1991 May;11(5):2842-51
pubmed: 1850105
Int J Mol Sci. 2022 Feb 11;23(4):
pubmed: 35216102
Nat Rev Genet. 2016 Jul;17(7):407-421
pubmed: 27240813
Science. 2010 Sep 24;329(5999):1650-3
pubmed: 20724583
BMC Res Notes. 2022 May 10;15(1):163
pubmed: 35538497
Biol Cell. 2005 Jan;97(1):87-96
pubmed: 15601260
Biochim Biophys Acta Mol Basis Dis. 2022 May 1;1868(5):166367
pubmed: 35158020
Genes (Basel). 2017 Mar 03;8(3):
pubmed: 28273791
J Clin Invest. 2017 Apr 3;127(4):1531-1545
pubmed: 28263188
J Biol Chem. 2011 Dec 30;286(52):44620-31
pubmed: 21937448
Wiley Interdiscip Rev RNA. 2015 Mar-Apr;6(2):243-56
pubmed: 25327818
Aging Cell. 2007 Aug;6(4):515-23
pubmed: 17559502
Mol Cell Biol. 2014 Jun;34(11):1942-55
pubmed: 24636994
BMC Med Genomics. 2011 Sep 27;4:67
pubmed: 21951698
J Cell Physiol. 2022 Aug;237(8):3328-3337
pubmed: 35621301
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Skelet Muscle. 2018 Jan 12;8(1):2
pubmed: 29329560
Stem Cell Res. 2012 Nov;9(3):261-9
pubmed: 23010573
Sci Rep. 2017 Nov 9;7(1):15131
pubmed: 29123152
Exp Biol Med (Maywood). 2018 Jan;243(2):118-128
pubmed: 29307280
Hum Mol Genet. 2019 Apr 15;28(8):1244-1259
pubmed: 30462217
J R Soc Interface. 2015 Jan 6;12(102):20140797
pubmed: 25551153
J Clin Invest. 2020 May 1;130(5):2465-2477
pubmed: 32250341
J Cell Sci. 2016 Nov 15;129(22):4305-4316
pubmed: 27672022
Histochem J. 2002 Oct;34(10):487-97
pubmed: 12945731
Nat Commun. 2019 May 23;10(1):2278
pubmed: 31123254
Muscle Nerve. 2021 Jan;63(1):60-67
pubmed: 32959362
Neurology. 2020 Mar 17;94(11):e1157-e1170
pubmed: 31964688
Sci Adv. 2019 Dec 11;5(12):eaaw7099
pubmed: 31844661
Clin Genet. 2020 Jun;97(6):799-814
pubmed: 32086799
J Cell Sci. 2016 Oct 15;129(20):3816-3831
pubmed: 27744317
Eur J Hum Genet. 2012 Apr;20(4):404-10
pubmed: 22108603
Oncotarget. 2016 Oct 4;7(40):65090-65108
pubmed: 27556182
Nat Commun. 2018 Mar 14;9(1):1075
pubmed: 29540680
Neuromuscul Disord. 2007 Aug;17(8):611-23
pubmed: 17588759
Orphanet J Rare Dis. 2021 Mar 12;16(1):129
pubmed: 33712050
J Med Genet. 2022 Feb;59(2):180-188
pubmed: 33436523
J Neuropathol Exp Neurol. 2022 Feb 24;81(3):172-181
pubmed: 35139534
Exp Neurol. 2008 Nov;214(1):87-96
pubmed: 18723017
PLoS One. 2016 Jan 27;11(1):e0146893
pubmed: 26816005
EMBO Mol Med. 2021 Aug 9;13(8):e13695
pubmed: 34151531
Nat Commun. 2017 Sep 15;8(1):550
pubmed: 28916757
Cell Mol Life Sci. 2013 Aug;70(15):2657-75
pubmed: 23069990
J Biol Chem. 2013 Dec 6;288(49):34989-5002
pubmed: 24145033
Elife. 2019 Jan 15;8:
pubmed: 30644821
Hum Mol Genet. 2020 Aug 11;29(14):2285-2299
pubmed: 32242220
Cell. 1996 Sep 6;86(5):731-41
pubmed: 8797820
FEBS Lett. 2022 Oct;596(20):2644-2658
pubmed: 35662006
Elife. 2016 Oct 15;5:
pubmed: 27743478
J Genet Genomics. 2020 Aug;47(8):466-476
pubmed: 33268291
Elife. 2015 Jan 07;4:
pubmed: 25564732
Int J Mol Sci. 2020 Jan 22;21(3):
pubmed: 31979100
Biomaterials. 2021 Aug;275:120973
pubmed: 34224984
EMBO J. 2008 Oct 22;27(20):2766-79
pubmed: 18833193
J Cell Sci. 2010 Aug 15;123(Pt 16):2685-96
pubmed: 20663914
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Annu Rev Genomics Hum Genet. 2019 Aug 31;20:265-291
pubmed: 31018108
PLoS Genet. 2010 Oct 28;6(10):e1001181
pubmed: 21060811
Hum Mol Genet. 2018 Jan 1;27(1):14-29
pubmed: 29040534
Stem Cell Reports. 2020 Sep 8;15(3):577-586
pubmed: 32822588
Hum Mol Genet. 2020 Sep 29;29(16):2746-2760
pubmed: 32744322
Transcription. 2019 Feb;10(1):1-20
pubmed: 30556762
PLoS One. 2009 Oct 15;4(10):e7482
pubmed: 19829708
Int J Mol Sci. 2020 Dec 30;22(1):
pubmed: 33396627
Cells. 2021 Mar 28;10(4):
pubmed: 33800595
Cell Stem Cell. 2016 Feb 4;18(2):243-52
pubmed: 26686466
Eur J Transl Myol. 2022 Mar 18;32(1):
pubmed: 35302338
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Hum Mol Genet. 2003 Nov 15;12(22):2895-907
pubmed: 14519683
BMC Biol. 2009 Jul 16;7:41
pubmed: 19607661
Nucleic Acids Res. 2012 Oct;40(19):9717-37
pubmed: 22904065
Int J Mol Sci. 2020 Aug 04;21(15):
pubmed: 32759720
Cell Rep. 2018 Nov 13;25(7):1800-1815.e4
pubmed: 30428349
Brain Dev. 1991 Sep;13(5):331-8
pubmed: 1723849
Int J Mol Sci. 2019 Oct 18;20(20):
pubmed: 31635221
Cell Stem Cell. 2016 Feb 4;18(2):160-2
pubmed: 26849298
Neurology. 2013 Feb 19;80(8):733-7
pubmed: 23365058
Mol Cell Biol. 2006 Nov;26(22):8437-47
pubmed: 16982691

Auteurs

Clothilde Claus (C)

Laboratory of Metabolic and Molecular Biochemistry, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium.

Moriya Slavin (M)

Department of Biological Chemistry, the Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, Israel.

Eugénie Ansseau (E)

Laboratory of Metabolic and Molecular Biochemistry, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium.

Céline Lancelot (C)

Laboratory of Metabolic and Molecular Biochemistry, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium.

Karimatou Bah (K)

Laboratory of Metabolic and Molecular Biochemistry, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium.

Saskia Lassche (S)

Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands.
Department of Neurology, Zuyderland Medical Center, Heerlen, the Netherlands.

Manon Fiévet (M)

Laboratory of Metabolic and Molecular Biochemistry, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium.

Anna Greco (A)

Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands.

Sara Tomaiuolo (S)

Laboratory of Metabolic and Molecular Biochemistry, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium.

Alexandra Tassin (A)

Laboratory of Metabolic and Molecular Biochemistry, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium.
Laboratory of Respiratory Physiology and Rehabilitation, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium.

Virginie Dudome (V)

Laboratory of Metabolic and Molecular Biochemistry, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium.

Benno Kusters (B)

Department of Pathology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands.

Anne-Emilie Declèves (AE)

Laboratory of Metabolic and Molecular Biochemistry, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium.

Dalila Laoudj-Chenivesse (D)

PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France.

Baziel G M van Engelen (BGM)

Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands.

Denis Nonclercq (D)

Laboratory of Histology, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium.

Alexandra Belayew (A)

Laboratory of Metabolic and Molecular Biochemistry, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium.

Nir Kalisman (N)

Department of Biological Chemistry, the Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, Israel.

Frédérique Coppée (F)

Laboratory of Metabolic and Molecular Biochemistry, Research Institute for Health Sciences and Technology, University of Mons, 6, Avenue du Champs de Mars, B-7000, Mons, Belgium. Frederique.coppee@umons.ac.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH